Why carry out this study?

GLP-1 agonists are effective in controlling type 2 diabetes but tend to lose efficacy over time.

Subcutaneously administered semaglutide is more efficacious in head-to-head studies compared with other GLP-1 agonists but data on switching GLP-1 agonist therapy to semaglutide is lacking.

We therefore investigated real-world efficacy of a treatment switch from GLP-1 agonists to semaglutide on glucose control and weight in patients with type 2 diabetes.

What was learned from the study?

Switching patients with pre-treated type 2 diabetes from GLP-1 analogue to subcutaneously administered semaglutide significantly reduces HbA1c and body weight over 6 months compared to baseline.

Equivalent dosing of semaglutide is effective, well tolerated and may be preferred over a stepwise dosing regimen when switching from other GLP-1 agonists.